Tennessee is currently home to 1929 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Clinical Assessment of Protopic® Ointment in Deep Partial-Thickness Burns
NCT05856994
Recruiting
There is currently no standard treatment to prevent burn depth conversion in partial-thickness burns. Conversion into deeper wounds is associated with higher complications and morbidity. The most common theory attributes this depth conversion to the prolonged inflammatory response that occurs after burn injury. Therefore, the investigators propose testing the safety and efficacy of tacrolimus ointment (an immunosuppressive agent) in patients with deep partial-thickness burns.
Gender:
ALL
Ages:
Between 50 years and 75 years
Trial Updated:
09/30/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Burn Injury
Register for Updates
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
NCT04569747
Recruiting
This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: * A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO) * Hormonal (endocrine) Treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/30/2024
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Register for Updates
Mechanisms of Gulf War Illness
NCT05972291
Recruiting
Many veterans with Gulf War Illness developed chronic gastrointestinal symptoms during their deployment to the Persian Gulf. The pathophysiologic mechanisms of these chronic gastrointestinal symptoms are not well understood but cause significant morbidity in veterans. Our proposed studies will provide an innovative and novel treatment trial for chronic gastrointestinal symptoms in veterans with Gulf War Illness that were deployed into war zones. Given that there are currently no specific treatme... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/27/2024
Locations: Memphis VA Medical Center, Memphis, TN, Memphis, Tennessee
Conditions: Gulf War Illness, Irritable Bowel Syndrome, Gastrointestinal Symptoms
Register for Updates
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
NCT05172973
Recruiting
The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects who are at high or greater risk with a failing aortic bioprosthetic valve.
Gender:
ALL
Ages:
All
Trial Updated:
09/27/2024
Locations: Saint Thomas Health, Nashville, Tennessee
Conditions: Aortic Valve Insufficiency, Aortic Valve Stenosis
Register for Updates
Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
NCT03929601
Recruiting
The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to a 2-hour mixed meal tolerance test, will be improved in participants with new onset T1D who are treated with Abatacept after Rituximab-pvvr compared to those treated with Rituximab-pvvr and placebo 24 months after enrollment.
Gender:
ALL
Ages:
Between 8 years and 45 years
Trial Updated:
09/27/2024
Locations: Vanderbilt Eskind Diabetes Center, Nashville, Tennessee
Conditions: Type 1 Diabetes Mellitus
Register for Updates
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
NCT04561362
Recruiting
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The primary endpoints are: Dose limiting toxicities (Parts A-1 and A-2), Overall response rate per RECIST v1.1 (Parts B1-B7), Safety and tolerability (Parts B-8, B-9 and C),... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Tennessee Oncology, PLLC, Nashville, Tennessee
Conditions: Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Ovarian Neoplasm, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms
Register for Updates
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
NCT02615184
Recruiting
Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach. The body uses stomach acid to break down food, but when acid rises up into the esophagus it can hurt or damage it. People with GERD often feel food coming back up into the throat and mouth and have a burning feeling in their stomach, chest, or throat, called heartburn. Other symptoms of G... Read More
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
09/25/2024
Locations: GI for Kids, Knoxville, Tennessee
Conditions: Erosive Esophagitis
Register for Updates
A Phase 3B Study to Evaluate Bone Mineral Density with Long-Term Use of Relugolix Combination Tablet in Women with Uterine Fibroids or Endometriosis
NCT05862272
Recruiting
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
09/24/2024
Locations: Chattanooga, Chattanooga, Tennessee
Conditions: Uterine Fibroids, Endometriosis
Register for Updates
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
NCT03827694
Recruiting
This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).
Gender:
ALL
Ages:
Between 120 days and 21 years
Trial Updated:
09/24/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Pulmonary Invasive Aspergillosis, Pulmonary Invasive Fungal Infections
Register for Updates
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
NCT05669833
Recruiting
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/23/2024
Locations: Cumberland Rheumatology, Crossville, Tennessee
Conditions: Psoriatic Arthritis
Register for Updates
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
NCT04620382
Recruiting
The purpose of this study is to learn more about the effects of abdominal compression and the medication midodrine, two interventions used for the treatment of orthostatic hypotension (low blood pressure on standing), on hemodynamic markers of cardiovascular risk. The study will be conducted at the Vanderbilt University Medical Center and consists of a screening and 2 testing days, one with abdominal compression and one with midodrine. The total length of the study will be about 5 days.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
09/20/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Neurogenic Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease
Register for Updates
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
NCT02429557
Recruiting
Compression garments have been shown to be effective in the treatment of orthostatic hypotension in autonomic failure patients. The purpose of this study is to determine the hemodynamic mechanisms by which abdominal compression (up to 40 mm Hg) improve the standing blood pressure and orthostatic tolerance in these patients, and to compare them with those of the standard of care midodrine. The investigators will test the hypothesis that abdominal compression will blunt the exaggerated fall in str... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/20/2024
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Orthostatic Hypotension, Pure Autonomic Failure, Multiple System Atrophy, Autonomic Failure
Register for Updates